New findings have emerged on the rapid regaining of weight following the cessation of weight-loss programs, this time focusing on anti-obesity medications (AOMs). Researchers are increasingly interested in these treatments as their use expands.
A team from Peking University in China analyzed data from 11 studies that included 2,466 participants. The studies featured a range of AOMs, particularly glucagon-like peptide-1 receptor agonists (GLP-1 drugs, like Ozempic and Wegovy), which mimic the natural hormone GLP-1, regulating both appetite and blood sugar levels.
The overall conclusion was that these medications helped individuals lose weight effectively. However, there was a common trend: weight often returned once patients stopped taking the drugs.
“Significant weight regain was observed eight weeks after the discontinuation of AOMs and persisted for up to 20 weeks,” the study’s leading author, Han Wu, reports. “Different patterns of weight regain were seen based on individual characteristics.”
Among the various weight-loss treatments examined, those in the GLP-1 category experienced the most significant weight rebound after ending treatment, which influenced the study results, as they constituted the majority analyzed.
After a 20-week period off the medications, participants had, on average, regained 2.5 kilograms (5.5 pounds). Interestingly, it was noted that individuals who lost the most weight also tended to regain more, which is, perhaps, a bit unexpected.
The researchers also factored in various other influences on weight, like physical activity levels and whether participants had diabetes, to get a clearer picture of the effects of stopping the medications.
The reasons behind this weight regain remain somewhat elusive. Future research may delve deeper into these underlying causes; there’s a theory that losing weight may somehow modify the body, making it harder to maintain a healthy weight.
The researchers noted that the implications of weight cycling on overall health and metabolism need further exploration.
One of the studies reviewed was published this year and indicated that participants who had stopped weekly injections of tirzepatide (or Zepbound) and switched to a placebo regained about half of the weight they had lost.
It’s important to recognize that this phenomenon is not exclusive to weight-loss drugs; similar issues have been observed with other methods of weight management, like gastric bypass surgeries.
This adds another layer to consider when evaluating the efficacy of AOMs, which may offer significant results but could also come with long-term consequences. Concerns about potential side effects and health risks linked to these medications have already been raised.
The research team is eager to see larger studies conducted over extended periods, as there may be better ways to assist individuals after they discontinue AOMs or perhaps even discover healthier alternatives.
In summary, the researchers urge for studies with longer follow-up durations to better understand the factors associated with weight changes post-treatment.
